Eudaimonia Partners’s AstraZeneca AZN Stock Holding History

Eudaimonia Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,576	Closed	-$213K	–	256
2023 Q3	$213K	Sell	1,576 -14	-0.9%	-$1.91K	0.05%	294
2023 Q2	$228K	Sell	1,590 -169	-10%	-$24.9K	0.05%	299
2023 Q1	$244K	Buy	1,759 +116	+7%	+$15.6K	0.06%	290
2022 Q4	$223K	Buy	+1,643	New	+$206K	0.05%	305
2022 Q3	–	Sell	-7,418	Closed	-$980K	–	344
2022 Q2	$980K	Buy	7,418 +664	+10%	+$87.1K	0.18%	135
2022 Q1	$896K	Buy	+6,754	New	+$810K	0.15%	164
2021 Q3	$867K	Buy	7,219 +470	+7%	+$54.7K	0.16%	161
2021 Q2	$808K	Sell	6,749 -588	-8%	-$64.5K	0.15%	165
2021 Q1	$729K	Sell	7,337 -153	-2%	-$15.4K	0.15%	154
2020 Q4	$749K	Buy	7,490 +477	+7%	+$50.5K	0.17%	140
2020 Q3	$769K	Buy	7,013 +2,420	+53%	+$269K	0.2%	121
2020 Q2	$486K	Buy	4,593 +656	+17%	+$67.8K	0.18%	129
2020 Q1	$352K	Buy	3,937 +2,500	+174%	+$235K	0.15%	157
2019 Q4	$143K	Buy	+1,437	New	+$135K	0.06%	291

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Eudaimonia Partners's AZN Position: Q4 2023 in Review

Eudaimonia Partners sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 1,576 shares — an estimated $213K sold.

Eudaimonia Partners first reported a position in AZN in Q4 2019 and held it in 14 quarters. The position peaked at $980K in Q2 2022. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Eudaimonia Partners reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Eudaimonia Partners sold 1,576 AstraZeneca shares in Q4 2023, an estimated $213K.
Eudaimonia Partners first reported a position in AstraZeneca in Q4 2019 and held it in 14 quarters.
Eudaimonia Partners's AstraZeneca position peaked at $980K in Q2 2022.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Eudaimonia Partners's 13F filing for Q4 2023, filed 8 Feb 2024.